About Us

The first meeting of the INMC was convened to provide a landscape overview of neoadjuvant melanoma treatment and research opportunities and challenges. With approximately 80 attendees from various disciplines and industries, the groundwork was laid to identify opportunities with ongoing projects and to align approaches future research.

A subsequent meeting was convened at the annual Society for Melanoma Research Congress, in Brisbane (Queensland, Australia) was convened to discuss and formalize trial design recommendations and guidelines for future studies and translational research considerations.

 In June, 2018 at ASCO in Chicago, IL, the goals and structure of the INMC were formalized and future plans for expansion and formalization of membership was initiated.

With over 350 registered members, the INMC continues to grow in membership and develop working groups to address key questions in the field.

Our Members

THE INMC IS ORGANIZED INTO WORKING GROUPS TO FURTHER ITS MISSION AND PURPOSE

• Clinical Trial Development and Design Working Group

• Translational Research and Biomarker Analysis Working Group

• Response Assessment Working Group

• Surgical Working Group